IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to develop a rationale for the selective treatment of small
fiber neuropathy with immune globulin (IVIG) in the appropriate patients.
The investigators hypothesize that individuals with auto-antibodies targeting neuronal
antigens (TS-HDS and FGFR3) and confirmed evidence of small fiber neuropathy (by skin biopsy
analysis of intra-epidermal nerve fiber density) will have an improvement in both nerve fiber
density and pain after treatment with immune globulin.
The co-primary endpoints will be a change in neuropathic pain (by VAS pain score) and a
change in intra-epidermal nerve fiber density (by punch skin biopsy).
The data gained from this pilot study will establish a rationale, with an appropriate
screening test, for the use of immune globulin for the treatment of small fiber neuropathy.